Buisson-Defferier S, Hibert M, van den Buuse M
Marion Merrell Dow Research Institute, Strasbourg Research Center, France.
Fundam Clin Pharmacol. 1993;7(9):499-511. doi: 10.1111/j.1472-8206.1993.tb00254.x.
The effects of intravenous (i.v.) administration of four agonists at central 5-HT1A receptors were investigated and compared. Acute iv injection of 0.1 mg/kg of 8-OH-DPAT induced a decrease in blood pressure both in spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY). The maximal hypotensive effect was observed 15 and 10 min after injection, respectively, but the effect was greater and longer-lasting in the SHR. 8-OH-DPAT significantly decreased heart rate in WKY and, to a lesser extent, in SHR. The i.v. injection of 1 mg/kg of flesinoxan caused a similar fall in blood pressure and heart rate in SHR and WKY. The i.v. administration of 1 mg/kg of 5-methyl-urapidil or MDL 75,608A caused a fall in blood pressure which was significantly more pronounced in SHR than in WKY. 5-methyl-urapidil induced a significant tachycardia in WKY, but had little effect on heart rate in SHR. MDL 75,608A caused a short-lasting tachycardia in SHR and WKY. In conscious SHR, the intracerebroventricular (icv) injection of 10 micrograms of 8-OH-DPAT or 100 micrograms of either flesinoxan or MDL 75,608A caused a decrease in blood pressure and heart rate. The icv injection of 100 micrograms of 5-methyl-urapidil caused only a decrease in blood pressure. Chronic pre-treatment with these compounds, by daily i.v. injection, did not significantly influence the hypotensive or bradycardic effects in an acute experiment. The involvement of alpha 1-adrenoceptors in the effects of these compounds was studied by administering phenylephrine (1 microgram/i.v.) at 5-min intervals before and after the i.v. injection of the experimental compounds. The injection of phenylephrine reproducibly increased blood pressure by 35-40 mm Hg after saline pre-treatment, and these responses were not affected by the i.v. injection of 0.1 mg/kg of either 8-OH-DPAT or 1 mg/kg of flesinoxan. In contrast, the phenylephrine-induced pressor responses were markedly diminished at 5 min after treatment with 1 mg/kg of either 5-methyl-urapidil or MDL 75,608A, but slowly recovered thereafter. These results show that the 5-HT1A receptor agonists 8-OH-DPAT, flesinoxan, 5-methyl-urapidil and MDL 75,608A show antihypertensive properties in conscious SHR after iv or icv injection. However, the mechanism of action of the compounds differs: 8-OH-DPAT and flesinoxan may act predominantly as 5-HT1A receptor agonists, where as 5-methyl-urapidil and MDL 75,608A also seem to have an effect on peripheral alpha 1-adrenoceptors.
研究并比较了四种中枢5-HT1A受体激动剂静脉注射(i.v.)的效果。急性静脉注射0.1mg/kg的8-OH-DPAT可使自发性高血压大鼠(SHR)和正常血压的Wistar-Kyoto大鼠(WKY)的血压降低。分别在注射后15分钟和10分钟观察到最大降压效果,但在SHR中效果更强且持续时间更长。8-OH-DPAT可显著降低WKY的心率,在SHR中降低程度较小。静脉注射1mg/kg的氟司必林可使SHR和WKY的血压和心率出现类似下降。静脉注射1mg/kg的5-甲基乌拉地尔或MDL 75,608A可使血压下降,在SHR中比在WKY中更明显。5-甲基乌拉地尔可使WKY出现显著心动过速,但对SHR的心率影响较小。MDL 75,608A可使SHR和WKY出现短暂心动过速。在清醒的SHR中,脑室内(icv)注射10μg的8-OH-DPAT或100μg的氟司必林或MDL 75,608A可使血压和心率降低。脑室内注射100μg的5-甲基乌拉地尔仅使血压降低。通过每日静脉注射用这些化合物进行慢性预处理,在急性实验中对降压或心动过缓作用没有显著影响。在静脉注射实验化合物之前和之后每隔5分钟静脉注射去氧肾上腺素(1μg/i.v.),研究α1-肾上腺素受体在这些化合物作用中的参与情况。在生理盐水预处理后,注射去氧肾上腺素可使血压反复升高35-40mmHg,这些反应不受静脉注射0.1mg/kg的8-OH-DPAT或1mg/kg的氟司必林的影响。相反,在用1mg/kg的5-甲基乌拉地尔或MDL 75,608A治疗后5分钟,去氧肾上腺素诱导的升压反应明显减弱,但此后缓慢恢复。这些结果表明,5-HT1A受体激动剂8-OH-DPAT、氟司必林、5-甲基乌拉地尔和MDL 75,608A在静脉或脑室内注射后对清醒的SHR具有降压特性。然而,这些化合物的作用机制不同:8-OH-DPAT和氟司必林可能主要作为5-HT1A受体激动剂起作用,而5-甲基乌拉地尔和MDL 75,608A似乎也对外周α1-肾上腺素受体有影响。